Profile data is unavailable for this security.
About the company
AbbVie Inc. is a diversified research-based biopharmaceutical company engaged in the research and development, manufacturing, commercialization and sale of medicines and therapies. It offers a comprehensive product portfolio across Immunology, Oncology, Neuroscience, Eye Care, Aesthetics, and Other Specialties. Immunology includes Rheumatology, Dermatology, and Gastroenterology. Oncology includes Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Lymphocytic Leukemia, Diffuse large B-cell lymphoma, and others. Neuroscience includes Parkinson's disease, Migraine, Movement Disorders, Psychiatric Disorders, and Alzheimer’s disease. Eye Care includes Chronic Dry Eye Disease, Glaucoma, Age-Related Retinal Diseases, and Refractive Disorders. Aesthetics includes Botox Cosmetic, The Juvederm Collection of Fillers, and others. It offers NX-13 for the treatment of ulcerative colitis (UC) and Crohn's disease (CD). It also offers CEL383 for the treatment of inflammatory bowel disease.
- Revenue in USD (TTM)55.53bn
- Net income in USD5.08bn
- Incorporated2012
- Employees50.00k
- LocationAbbVie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
- Phone+1 (847) 932-7900
- Fax+1 (302) 655-5049
- Websitehttps://www.abbvie.com/
Mergers & acquisitions
| Acquired company | ABBV:NYQ since announced | Transaction value |
|---|---|---|
| Aliada Therapeutics Inc | 6.20% | 1.40bn |
| Celsius Therapeutics Inc | 16.56% | 250.00m |
| Cerevel Therapeutics Holdings Inc | 38.00% | 8.70bn |
| ImmunoGen Inc | 44.04% | 10.22bn |
